Products & Services
We are excited to announce our success to innovate test-based programs utilising the CE-IVD Dysbiosis test for inflammatory bowel disease (GA-map). In addition, we licensed-in intellectual property and secured freedom-to-operate in Europe for the first multiplex assay to classify breast cancer. Ongoing projects include the M3 Profiler aiming to characterise exosomes in cancer patients, and the upcoming launch of Lifestyle medicine clinics in collaboration with our local and international partners. We have aligned with European associations and the press releases shall be communicated in the next few months.
Join us in our mission:
- Prevention of colorectal cancer is high on our agenda. Learn more about the Gut restore program as an actionable tool to reduce intestinal inflammation.
- An RUO molecular classification of breast cancer is now approved for sale in Europe.
- Our R&D embarked on setting up sensitive techniques to measure biomarkers in blood-derived exosomes.
- Our professional team is seeking partnerships to enhance market entry and develop new products.
- Our commercial team is providing high quality reagents for research institutions, including cutting edge emerging technologies and services.
Projects & Innovations
RESEARCH
Health Talks
Corporate Health Talks on Lifestyle Medicine. The main topic is to use lifestyle interventions to enhance performance to excellence.
Gut Restore Program
A 6-month program to restore intestinal function. Includes microbiota and lipid profile test. Now available from Saint James Hospitals (Malta).
Lifestyle Health Hub
Omnigene obtained technology transfer of the GA-map dysbiosis test. Innovative programs offer Lifestyle interventions, targeting IBS, PCOS, auto-immunity, sports performance, corporate wellness, amongst others.
Previous Projects
Omnigene was involved in various research projects.
A molecular test was developed that measures COVID-19 (SARS-CoV-2) immune response for vaccine surveillance.
BOOKIND.
A companion diagnostic product that predicts use of specific therapeutics in Epilepsy.
Who Are We ?
About Us
The executive team brings together a wealth of experience in health management, quality standards, commercial licensing, scientific excellence and product development & innovation. Together with the scientific team the company invested in research projects to enable innovations and secured international reputation with more than 10 partners globally.
- innovative cancer tests
- accurate & sensitive measurements
- enable use of low input, low quality precious patient material
- clinical relevant solutions in oncology
- competitive prices
10+
international partners
1000+
Hours of Research & Innovation
10+
Years Experience
What our partners have to say
Testimonial
Dr Ruud Jorna, Key Account Manager, Luminex Licensed Technologies Group EMEA said, 'Professor Grech has been a great advocate for multiplexing, as exemplified by his valuable contribution to our xMAP Connect events. We are confident that Professor’s Grech work will contribute towards a simpler and better way of diagnosing breast cancer.'
Andreas M Kaufmann, PhD, of Gynecologic Tumor Immunology and HPV Laboratory at the Department for Gynecology at Charité-Universitaetsmedizin Berlin, Germany
"As a research laboratory we are looking for simple and robust test systems that give a multitude of information on a sample and in an observer independent and unbiased way. We have used the SimpliPlex Breast Cancer multiplex test from Omnigene on breast biopsy FFPE samples from our collaboration partners in sub-saharan Africa. Pathological diagnoses are sometimes difficult to obtain timely and accurate in LMIC but also in HIC. There may be delays and interobserver variations as microscopical images are more difficult to quantify and to standardize. The clinical impact on patient therapy can only be estimated. A molecular method like a multiplexed, quantitative expression measurement as it is obtained by this innovative approach and technology can ameliorate problems of misdiagnosis and observer-dependent interpretation. Since processing is simple, standardized and high-throughput and interpretation is unbiased I regard this technology an example of a breakthrough development for patient care."
Ronny Hermansen, CEO, Genetic Analysis, comments: “GA is proud to have Omnigene Medical Technologies Ltd as a partner. The GA-map® platform will offer a fast turnaround lab testing service with an integrated software algorithm for immediate result presentation We believe microbiome testing will soon be a game-changer in medicine and the distribution agreement is well in line with our business strategy to expand to new markets.”
